A severe case of bevacizumab-induced thrombotic microangiopathy

---

Copy For Citation

Bektas M., Samanci N., Cokgezer S., Keskin D., Demirelli F. H.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.25, no.7, pp.1754-1757, 2019 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 25 Issue: 7
• Publication Date: 2019
• Doi Number: 10.1177/1078155218800371
• Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.1754-1757
• Istanbul University Affiliated: Yes

Abstract

Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.